About
Built to make peptide claims inspectable.
AminoBrief is an early-stage evidence and education platform. The product is being developed around claim-level sources, visible uncertainty, accountable review, corrections, and strict boundaries around patient-specific use.
Why it exists
Peptide information is often compressed into a verdict before the reader can see the source type, studied population, product identity, jurisdiction, or limitation. AminoBrief reverses that order: evidence and scope first, conclusion second.
What it is not
AminoBrief is not a pharmacy, clinic, prescriber, product-authentication service, dosing service, or substitute for medical care. The public platform does not sell peptides.
Operator disclosure
AminoBrief is currently an early-stage project led by David Secul. Clinical, legal, and scientific reviewer appointments will be disclosed when active rather than implied in advance.